Achilles Therapeutics plc
ACHL
$1.48
$0.010.68%
| 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 4.02M | 4.16M | 4.16M | 3.62M | 4.38M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 20.42M | 17.80M | 14.30M | 19.41M | 19.10M |
| Operating Income | -20.42M | -17.80M | -14.30M | -19.41M | -19.10M |
| Income Before Tax | -19.60M | -16.37M | -12.30M | -18.13M | -16.71M |
| Income Tax Expenses | -5.00K | 8.00K | -23.00K | 505.00K | -24.00K |
| Earnings from Continuing Operations | -19.60M | -16.38M | -12.27M | -18.63M | -16.68M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -19.60M | -16.38M | -12.27M | -18.63M | -16.68M |
| EBIT | -20.42M | -17.80M | -14.30M | -19.41M | -19.10M |
| EBITDA | -19.22M | -16.62M | -13.12M | -18.27M | -17.89M |
| EPS Basic | -0.48 | -0.41 | -0.30 | -0.46 | -0.42 |
| Normalized Basic EPS | -0.30 | -0.25 | -0.19 | -0.28 | -0.26 |
| EPS Diluted | -0.48 | -0.41 | -0.30 | -0.46 | -0.42 |
| Normalized Diluted EPS | -0.30 | -0.25 | -0.19 | -0.28 | -0.26 |
| Average Basic Shares Outstanding | 40.43M | 40.36M | 40.28M | 40.19M | 40.07M |
| Average Diluted Shares Outstanding | 40.43M | 40.36M | 40.28M | 40.19M | 40.07M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
